Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AVITA Medical, Inc.RCEL · Entity 5905 | Chief Financial Officer | July 01, 2022 | July 06, 2022 |
| Cytek Biosciences, Inc.CTKB · Entity 5345 | Director | August 18, 2026 | August 20, 2026 |
| MDxHealth SAMDXH · Entity 7018 | Director | June 01, 2026 | June 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AVITA Medical, Inc.
Report date July 01, 2022 · Filed July 06, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 46,450 |
Reported balance
After 2022-07-01 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2022-07-01 · Grant · Acquired 35,950 · Balance 46,450 F1: Reflects Restricted Stock Units, each representing a contingent right to be issued one share of Common Stock. These Restricted Stock Units vest in four equal annual installments beginning on August 20, 2023. F2: Includes unvested Restricted Stock Units. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.97 · Expires 2032-07-01 | Direct | 20,650 |
Reported balance
After 2022-07-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-07-01 · Grant · Acquired 20,650 · Balance 20,650 F3: These Stock Options vest in four equal annual installments beginning on August 20, 2023. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects Restricted Stock Units, each representing a contingent right to be issued one share of Common Stock. These Restricted Stock Units vest in four equal annual installments beginning on August 20, 2023.
F2: Includes unvested Restricted Stock Units.
F3: These Stock Options vest in four equal annual installments beginning on August 20, 2023.
Cytek Biosciences, Inc.
Report date August 18, 2026 · Filed August 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 62,875 |
Reported balance
After 2026-08-18 transaction · row 1
1 source rowRow 1 · 2026-08-18 · Exercise / conversion · Acquired 2,181 · Balance 62,875 F1: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 7,276 |
Reported balance
After 2026-08-18 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-08-18 · Exercise / conversion · Disposed 2,181 · Balance 7,276 F1: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F2: The shares underlying the RSU Award shall vest over 3 years, with 2/36 of the total shares underlying the RSU Award vesting on August 18, 2024; 3/36 of the total shares underlying the RSU Award vesting on November 18, 2024 and each November 18 thereafter; 4/36 of the total shares underlying the RSU Award vesting on March 10, 2025 and each March 10 thereafter; 2/36 of the total shares underlying the RSU Award vesting on May 18, 2025 and each May 18 thereafter; and 3/36 of the total shares underlying the RSU Award vesting on August 18, 2025 and each August 18 thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock.
F2: The shares underlying the RSU Award shall vest over 3 years, with 2/36 of the total shares underlying the RSU Award vesting on August 18, 2024; 3/36 of the total shares underlying the RSU Award vesting on November 18, 2024 and each November 18 thereafter; 4/36 of the total shares underlying the RSU Award vesting on March 10, 2025 and each March 10 thereafter; 2/36 of the total shares underlying the RSU Award vesting on May 18, 2025 and each May 18 thereafter; and 3/36 of the total shares underlying the RSU Award vesting on August 18, 2025 and each August 18 thereafter.
MDxHealth SA
Report date June 01, 2026 · Filed June 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Share OptionSEC Table II · derivative / convertible security · Conversion / exercise price $0.76 · Expires 2036-05-28 | Direct | 10,000 |
Reported balance
After 2026-06-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-01 · Grant · Acquired 10,000 · Balance 10,000 F1: Represents options to purchase 10,000 ordinary shares of the Issuer at a price per share of $0.76 granted on June 1, 2026 which vest in full on the date of the annual general shareholders' meeting that takes place in the calendar year following the calendar year in which the options were granted. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents options to purchase 10,000 ordinary shares of the Issuer at a price per share of $0.76 granted on June 1, 2026 which vest in full on the date of the annual general shareholders' meeting that takes place in the calendar year following the calendar year in which the options were granted.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 18, 2026 Filed Aug 20, 2026 20:28 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionRestricted Stock Units · Derivative | 2,181 | $0.00 | $0.00 |
DisclosureSEC source: 0001515140-26-000005 · form4-08202026_080828.xml · derivative · entry 2 Holder Michael · CIK 0001515140 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,276 Underlying: Common Stock · 2,181 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: The shares underlying the RSU Award shall vest over 3 years, with 2/36 of the total shares underlying the RSU Award vesting on August 18, 2024; 3/36 of the total shares underlying the RSU Award vesting on November 18, 2024 and each November 18 thereafter; 4/36 of the total shares underlying the RSU Award vesting on March 10, 2025 and each March 10 thereafter; 2/36 of the total shares underlying the RSU Award vesting on May 18, 2025 and each May 18 thereafter; and 3/36 of the total shares underlying the RSU Award vesting on August 18, 2025 and each August 18 thereafter. F2 · derivative.expiration_date: The shares underlying the RSU Award shall vest over 3 years, with 2/36 of the total shares underlying the RSU Award vesting on August 18, 2024; 3/36 of the total shares underlying the RSU Award vesting on November 18, 2024 and each November 18 thereafter; 4/36 of the total shares underlying the RSU Award vesting on March 10, 2025 and each March 10 thereafter; 2/36 of the total shares underlying the RSU Award vesting on May 18, 2025 and each May 18 thereafter; and 3/36 of the total shares underlying the RSU Award vesting on August 18, 2025 and each August 18 thereafter. Read SEC document |
| August 18, 2026 Filed Aug 20, 2026 20:28 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionCommon Stock | 2,181 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001515140-26-000005 · form4-08202026_080828.xml · nonDerivative · entry 1 Holder Michael · CIK 0001515140 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,875 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| June 10, 2026 Filed Jun 12, 2026 23:22 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionRestricted Stock Units · Derivative | 43,973 | $0.00 | $0.00 |
DisclosureSEC source: 0001515140-26-000003 · form4-06122026_110655.xml · derivative · entry 4 Holder Michael · CIK 0001515140 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 43,973 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F4 · derivative.exercise_date: 100% of the shares subject to the RSU Award vested on June 10, 2026. F4 · derivative.expiration_date: 100% of the shares subject to the RSU Award vested on June 10, 2026. Read SEC document |
| June 10, 2026 Filed Jun 12, 2026 23:22 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | GrantDirector Stock Option (right to buy) · Derivative | 18,261 | $0.00 Strike: $4.05 | $0.00 |
DisclosureSEC source: 0001515140-26-000003 · form4-06122026_110655.xml · derivative · entry 3 Holder Michael · CIK 0001515140 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,261 Underlying: Common Stock · 18,261 shares Expires 2036-06-10 F3 · derivative.exercise_date: 100% of the shares subject to the option shall vest on the earlier of June 10, 2027 and the date of the Issuer's 2027 annual meeting of stockholders (provided such meeting is held in June 2027). Read SEC document |
| June 10, 2026 Filed Jun 12, 2026 23:22 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | GrantRestricted Stock Units · Derivative | 33,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001515140-26-000003 · form4-06122026_110655.xml · derivative · entry 2 Holder Michael · CIK 0001515140 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,333 Underlying: Common Stock · 33,333 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: 100% of the shares subject to the RSU Award shall vest on the earlier of June 10, 2027 and the date of the Issuer's 2027 annual meeting of stockholders (provided such meeting is held in June 2027). F2 · derivative.expiration_date: 100% of the shares subject to the RSU Award shall vest on the earlier of June 10, 2027 and the date of the Issuer's 2027 annual meeting of stockholders (provided such meeting is held in June 2027). Read SEC document |
| June 10, 2026 Filed Jun 12, 2026 23:22 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionCommon Stock | 43,973 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001515140-26-000003 · form4-06122026_110655.xml · nonDerivative · entry 1 Holder Michael · CIK 0001515140 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,694 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| June 01, 2026 Filed Jun 3, 2026 21:30 UTC | MDxHealth SA MDXH · Entity 7018 | GrantShare Option · Derivative | 10,000 | $0.00 Strike: $0.76 | $0.00 |
DisclosureSEC source: 0001193125-26-255808 · ownership.xml · derivative · entry 1 Holder Michael · CIK 0001515140 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Ordinary Shares · 10,000 shares Expires 2036-05-28 F1 · derivative.exercise_date: Represents options to purchase 10,000 ordinary shares of the Issuer at a price per share of $0.76 granted on June 1, 2026 which vest in full on the date of the annual general shareholders' meeting that takes place in the calendar year following the calendar year in which the options were granted. Read SEC document |
| May 18, 2026 Filed May 20, 2026 22:01 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionRestricted Stock Units · Derivative | 1,454 | $0.00 | $0.00 |
DisclosureSEC source: 0001515140-26-000002 · form4-05202026_100527.xml · derivative · entry 2 Holder Michael · CIK 0001515140 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,457 Underlying: Common Stock · 1,454 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: 2/36 of the total shares subject to the RSU Award shall vest on August 18, 2024; 3/36 of the total shares subject to the RSU Award shall vest on November 18, 2024 and each November 18 thereafter; 4/36 of the total shares underlying the RSU Award shall vest on March 10, 2025 and each March 10 thereafter; 2/36 of the total shares underlying the RSU Award vesting shall vest on May 18, 2025 and each May 18 thereafter; and 3/36 of the total shares underlying the RSU Award shall vest on August 18, 2025 and each August 18 thereafter, until fully vested. F2 · derivative.expiration_date: 2/36 of the total shares subject to the RSU Award shall vest on August 18, 2024; 3/36 of the total shares subject to the RSU Award shall vest on November 18, 2024 and each November 18 thereafter; 4/36 of the total shares underlying the RSU Award shall vest on March 10, 2025 and each March 10 thereafter; 2/36 of the total shares underlying the RSU Award vesting shall vest on May 18, 2025 and each May 18 thereafter; and 3/36 of the total shares underlying the RSU Award shall vest on August 18, 2025 and each August 18 thereafter, until fully vested. Read SEC document |
| May 18, 2026 Filed May 20, 2026 22:01 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionCommon Stock | 1,454 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001515140-26-000002 · form4-05202026_100527.xml · nonDerivative · entry 1 Holder Michael · CIK 0001515140 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,721 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| March 10, 2026 Filed Mar 12, 2026 20:34 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionRestricted Stock Units · Derivative | 2,908 | $0.00 | $0.00 |
DisclosureSEC source: 0001515140-26-000001 · form4-03122026_080344.xml · derivative · entry 2 Holder Michael · CIK 0001515140 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,911 Underlying: Common Stock · 2,908 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: 2/36 of the total shares subject to the RSU Award shall vest on August 18, 2024; 3/36 of the total shares subject to the RSU Award shall vest on November 18, 2024 and each November 18 thereafter; 4/36 of the total shares underlying the RSU Award shall vest on March 10, 2025 and each March 10 thereafter; 2/36 of the total shares underlying the RSU Award vesting shall vest on May 18, 2025 and each May 18 thereafter; and 3/36 of the total shares underlying the RSU Award shall vest on August 18, 2025 and each August 18 thereafter, until fully vested. F2 · derivative.expiration_date: 2/36 of the total shares subject to the RSU Award shall vest on August 18, 2024; 3/36 of the total shares subject to the RSU Award shall vest on November 18, 2024 and each November 18 thereafter; 4/36 of the total shares underlying the RSU Award shall vest on March 10, 2025 and each March 10 thereafter; 2/36 of the total shares underlying the RSU Award vesting shall vest on May 18, 2025 and each May 18 thereafter; and 3/36 of the total shares underlying the RSU Award shall vest on August 18, 2025 and each August 18 thereafter, until fully vested. Read SEC document |
| March 10, 2026 Filed Mar 12, 2026 20:34 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionCommon Stock | 2,908 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001515140-26-000001 · form4-03122026_080344.xml · nonDerivative · entry 1 Holder Michael · CIK 0001515140 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,267 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| November 18, 2025 Filed Nov 20, 2025 23:53 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionRestricted Stock Units · Derivative | 2,181 | $0.00 | $0.00 |
DisclosureSEC source: 0001515140-25-000002 · form4-11202025_111124.xml · derivative · entry 2 Holder Michael · CIK 0001515140 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,819 Underlying: Common Stock · 2,181 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: 2/36 of the total shares subject to the RSU Award shall vest on August 18, 2024; 3/36 of the total shares subject to the RSU Award shall vest on November 18, 2024 and each November 18 thereafter; 4/36 of the total shares underlying the RSU Award shall vest on March 10, 2025 and each March 10 thereafter; 2/36 of the total shares underlying the RSU Award vesting shall vest on May 18, 2025 and each May 18 thereafter; and 3/36 of the total shares underlying the RSU Award shall vest on August 18, 2025 and each August 18 thereafter, until fully vested. F2 · derivative.expiration_date: 2/36 of the total shares subject to the RSU Award shall vest on August 18, 2024; 3/36 of the total shares subject to the RSU Award shall vest on November 18, 2024 and each November 18 thereafter; 4/36 of the total shares underlying the RSU Award shall vest on March 10, 2025 and each March 10 thereafter; 2/36 of the total shares underlying the RSU Award vesting shall vest on May 18, 2025 and each May 18 thereafter; and 3/36 of the total shares underlying the RSU Award shall vest on August 18, 2025 and each August 18 thereafter, until fully vested. Read SEC document |
| November 18, 2025 Filed Nov 20, 2025 23:53 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionCommon Stock | 2,181 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001515140-25-000002 · form4-11202025_111124.xml · nonDerivative · entry 1 Holder Michael · CIK 0001515140 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,359 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| August 18, 2025 Filed Aug 20, 2025 21:43 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionRestricted Stock Units · Derivative | 2,181 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-022518 · form4-08202025_090800.xml · derivative · entry 2 Holder Michael · CIK 0001515140 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 2,181 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: 2/36 of the total shares subject to the RSU Award shall vest on August 18, 2024; 3/36 of the total shares subject to the RSU Award shall vest on November 18, 2024 and each November 18 thereafter; 4/36 of the total shares underlying the RSU Award shall vest on March 10, 2025 and each March 10 thereafter; 2/36 of the total shares underlying the RSU Award vesting shall vest on May 18, 2025 and each May 18 thereafter; and 3/36 of the total shares underlying the RSU Award shall vest on August 18, 2025 and each August 18 thereafter, until fully vested. F2 · derivative.expiration_date: 2/36 of the total shares subject to the RSU Award shall vest on August 18, 2024; 3/36 of the total shares subject to the RSU Award shall vest on November 18, 2024 and each November 18 thereafter; 4/36 of the total shares underlying the RSU Award shall vest on March 10, 2025 and each March 10 thereafter; 2/36 of the total shares underlying the RSU Award vesting shall vest on May 18, 2025 and each May 18 thereafter; and 3/36 of the total shares underlying the RSU Award shall vest on August 18, 2025 and each August 18 thereafter, until fully vested. Read SEC document |
| August 18, 2025 Filed Aug 20, 2025 21:43 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionCommon Stock | 2,181 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-022518 · form4-08202025_090800.xml · nonDerivative · entry 1 Holder Michael · CIK 0001515140 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,178 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 18, 2025 Filed Jun 20, 2025 20:18 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | GrantDirector Stock Option (right to buy) · Derivative | 23,809 | $0.00 Strike: $3.07 | $0.00 |
DisclosureSEC source: 0001415889-25-017840 · form4-06202025_080658.xml · derivative · entry 2 Holder Michael · CIK 0001515140 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,809 Underlying: Common Stock · 23,809 shares Expires 2035-06-18 F3 · derivative.exercise_date: 100% of the shares subject to the option shall vest on the earlier of June 18, 2026 and the date of the Issuer's 2026 annual meeting of stockholders (provided such meeting is held in June 2026). Read SEC document |
| June 18, 2025 Filed Jun 20, 2025 20:18 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | GrantRestricted Stock Units · Derivative | 43,973 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-017840 · form4-06202025_080658.xml · derivative · entry 1 Holder Michael · CIK 0001515140 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,973 Underlying: Common Stock · 43,973 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: 100% of the shares subject to the RSU Award shall vest on the earlier of June 18, 2026 and the date of the Issuer's 2026 annual meeting of stockholders (provided such meeting is held in June 2026). F2 · derivative.expiration_date: 100% of the shares subject to the RSU Award shall vest on the earlier of June 18, 2026 and the date of the Issuer's 2026 annual meeting of stockholders (provided such meeting is held in June 2026). Read SEC document |
| May 19, 2025 Filed May 21, 2025 21:48 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionRestricted Stock Units · Derivative | 1,454 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-013974 · form4-05212025_090559.xml · derivative · entry 2 Holder Michael · CIK 0001515140 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,181 Underlying: Common Stock · 1,454 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: 2/36 of the total shares subject to the RSU Award shall vest on August 18, 2024; 3/36 of the total shares subject to the RSU Award shall vest on November 18, 2024 and each November 18 thereafter; 4/36 of the total shares underlying the RSU Award shall vest on March 10, 2025 and each March 10 thereafter; 2/36 of the total shares underlying the RSU Award vesting shall vest on May 18, 2025 and each May 18 thereafter; and 3/36 of the total shares underlying the RSU Award shall vest on August 18, 2025 and each August 18 thereafter, until fully vested. F2 · derivative.expiration_date: 2/36 of the total shares subject to the RSU Award shall vest on August 18, 2024; 3/36 of the total shares subject to the RSU Award shall vest on November 18, 2024 and each November 18 thereafter; 4/36 of the total shares underlying the RSU Award shall vest on March 10, 2025 and each March 10 thereafter; 2/36 of the total shares underlying the RSU Award vesting shall vest on May 18, 2025 and each May 18 thereafter; and 3/36 of the total shares underlying the RSU Award shall vest on August 18, 2025 and each August 18 thereafter, until fully vested. Read SEC document |
| May 19, 2025 Filed May 21, 2025 21:48 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionCommon Stock | 1,454 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-013974 · form4-05212025_090559.xml · nonDerivative · entry 1 Holder Michael · CIK 0001515140 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,997 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| March 10, 2025 Filed Mar 12, 2025 21:47 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionRestricted Stock Units · Derivative | 2,908 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-007887 · form4-03122025_090354.xml · derivative · entry 2 Holder Michael · CIK 0001515140 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,635 Underlying: Common Stock · 2,908 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: 2/36 of the total shares subject to the RSU Award shall vest on August 18, 2024; 3/36 of the total shares subject to the RSU Award shall vest on November 18, 2024 and each November 18 thereafter; 4/36 of the total shares underlying the RSU Award shall vest on March 10, 2025 and each March 10 thereafter; 2/36 of the total shares underlying the RSU Award vesting shall vest on May 18, 2025 and each May 18 thereafter; and 3/36 of the total shares underlying the RSU Award shall vest on August 18, 2025 and each August 18 thereafter, until fully vested. F2 · derivative.expiration_date: 2/36 of the total shares subject to the RSU Award shall vest on August 18, 2024; 3/36 of the total shares subject to the RSU Award shall vest on November 18, 2024 and each November 18 thereafter; 4/36 of the total shares underlying the RSU Award shall vest on March 10, 2025 and each March 10 thereafter; 2/36 of the total shares underlying the RSU Award vesting shall vest on May 18, 2025 and each May 18 thereafter; and 3/36 of the total shares underlying the RSU Award shall vest on August 18, 2025 and each August 18 thereafter, until fully vested. Read SEC document |
| March 10, 2025 Filed Mar 12, 2025 21:47 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionCommon Stock | 2,908 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-007887 · form4-03122025_090354.xml · nonDerivative · entry 1 Holder Michael · CIK 0001515140 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,543 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| November 18, 2024 Filed Nov 20, 2024 23:16 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionRestricted Stock Units · Derivative | 2,181 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-027364 · form4-11202024_111103.xml · derivative · entry 2 Holder Michael · CIK 0001515140 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,543 Underlying: Common Stock · 2,181 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: 2/36 of the total shares subject to the RSU Award shall vest on August 18, 2024; 3/36 of the total shares subject to the RSU Award shall vest on November 18, 2024 and each November 18 thereafter; 4/36 of the total shares underlying the RSU Award shall vest on March 10, 2025 and each March 10 thereafter; 2/36 of the total shares underlying the RSU Award vesting shall vest on May 18, 2025 and each May 18 thereafter; and 3/36 of the total shares underlying the RSU Award shall vest on August 18, 2025 and each August 18 thereafter, until fully vested. F2 · derivative.expiration_date: 2/36 of the total shares subject to the RSU Award shall vest on August 18, 2024; 3/36 of the total shares subject to the RSU Award shall vest on November 18, 2024 and each November 18 thereafter; 4/36 of the total shares underlying the RSU Award shall vest on March 10, 2025 and each March 10 thereafter; 2/36 of the total shares underlying the RSU Award vesting shall vest on May 18, 2025 and each May 18 thereafter; and 3/36 of the total shares underlying the RSU Award shall vest on August 18, 2025 and each August 18 thereafter, until fully vested. Read SEC document |
| November 18, 2024 Filed Nov 20, 2024 23:16 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionCommon Stock | 2,181 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-027364 · form4-11202024_111103.xml · nonDerivative · entry 1 Holder Michael · CIK 0001515140 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,635 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| August 19, 2024 Filed Aug 21, 2024 22:28 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionRestricted Stock Units · Derivative | 1,454 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-021864 · form4-08212024_100824.xml · derivative · entry 2 Holder Michael · CIK 0001515140 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,724 Underlying: Common Stock · 1,454 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: 2/36 of the total shares subject to the RSU Award shall vest on August 18, 2024; 3/36 of the total shares subject to the RSU Award shall vest on November 18, 2024 and each November 18 thereafter; 4/36 of the total shares underlying the RSU Award shall vest on March 10, 2025 and each March 10 thereafter; 2/36 of the total shares underlying the RSU Award vesting shall vest on May 18, 2025 and each May 18 thereafter; and 3/36 of the total shares underlying the RSU Award shall vest on August 18, 2025 and each August 18 thereafter, until fully vested. F2 · derivative.expiration_date: 2/36 of the total shares subject to the RSU Award shall vest on August 18, 2024; 3/36 of the total shares subject to the RSU Award shall vest on November 18, 2024 and each November 18 thereafter; 4/36 of the total shares underlying the RSU Award shall vest on March 10, 2025 and each March 10 thereafter; 2/36 of the total shares underlying the RSU Award vesting shall vest on May 18, 2025 and each May 18 thereafter; and 3/36 of the total shares underlying the RSU Award shall vest on August 18, 2025 and each August 18 thereafter, until fully vested. Read SEC document |
| August 19, 2024 Filed Aug 21, 2024 22:28 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionCommon Stock | 1,454 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-021864 · form4-08212024_100824.xml · nonDerivative · entry 1 Holder Michael · CIK 0001515140 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,454 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| June 05, 2024 Filed Jun 7, 2024 23:09 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | GrantStock Option (right to buy) · Derivative | 37,878 | $0.00 Strike: $5.73 | $0.00 |
DisclosureSEC source: 0001415889-24-016083 · form4-06072024_110607.xml · derivative · entry 2 Holder Michael · CIK 0001515140 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,878 Underlying: Common Stock · 37,878 shares Expires 2034-06-05 F3 · derivative.exercise_date: 1/36 of the total shares subject to the option shall vest monthly over 3 years following the grant date of June 5, 2024. Read SEC document |
| June 05, 2024 Filed Jun 7, 2024 23:09 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | GrantRestricted Stock Units · Derivative | 26,178 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-016083 · form4-06072024_110607.xml · derivative · entry 1 Holder Michael · CIK 0001515140 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,178 Underlying: Common Stock · 26,178 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: 2/36 of the total shares subject to the RSU Award shall vest on August 18, 2024; 3/36 of the total shares subject to the RSU Award shall vest on November 18, 2024 and each November 18 thereafter; 4/36 of the total shares underlying the RSU Award shall vest on March 10, 2025 and each March 10 thereafter; 2/36 of the total shares underlying the RSU Award vesting shall vest on May 18, 2025 and each May 18 thereafter; and 3/36 of the total shares underlying the RSU Award shall vest on August 18, 2025 and each August 18 thereafter, until fully vested. F2 · derivative.expiration_date: 2/36 of the total shares subject to the RSU Award shall vest on August 18, 2024; 3/36 of the total shares subject to the RSU Award shall vest on November 18, 2024 and each November 18 thereafter; 4/36 of the total shares underlying the RSU Award shall vest on March 10, 2025 and each March 10 thereafter; 2/36 of the total shares underlying the RSU Award vesting shall vest on May 18, 2025 and each May 18 thereafter; and 3/36 of the total shares underlying the RSU Award shall vest on August 18, 2025 and each August 18 thereafter, until fully vested. Read SEC document |
| July 01, 2022 Filed Jul 6, 2022 22:57 UTC | AVITA Medical, Inc. RCEL · Entity 5905 | GrantStock Options (Right to Buy) · Derivative | 20,650 | $0.00 Strike: $4.97 | $0.00 |
DisclosureSEC source: 0001209191-22-041378 · doc4.xml · derivative · entry 2 Holder Michael · CIK 0001515140 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,650 Underlying: Common Stock · 20,650 shares Expires 2032-07-01 F3 · derivative.exercise_date: These Stock Options vest in four equal annual installments beginning on August 20, 2023. Read SEC document |
| July 01, 2022 Filed Jul 6, 2022 22:57 UTC | AVITA Medical, Inc. RCEL · Entity 5905 | GrantCommon Stock | 35,950 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-041378 · doc4.xml · nonDerivative · entry 1 Holder Michael · CIK 0001515140 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,450 F1 · price: Reflects Restricted Stock Units, each representing a contingent right to be issued one share of Common Stock. These Restricted Stock Units vest in four equal annual installments beginning on August 20, 2023. F2 · balance_after: Includes unvested Restricted Stock Units. Read SEC document |
| July 06, 2021 Filed Sep 7, 2021 20:05 UTC | AVITA Medical, Inc. RCEL · Entity 5905 | GrantStock Options (Right to Buy) · Derivative | 6,925 | $0.00 Strike: $20.21 | $0.00 |
DisclosureSEC source: 0001209191-21-054959 · doc4.xml · derivative · entry 2 Holder Michael · CIK 0001515140 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,925 Underlying: Common Stock · 6,925 shares Expires 2031-07-06 F3 · derivative.exercise_date: These Stock Options vest in four equal annual installments upon the satisfaction of certain performance-based vesting criteria with respect to the particular portion of such Stock Options. Read SEC document |
| July 06, 2021 Filed Sep 7, 2021 20:05 UTC | AVITA Medical, Inc. RCEL · Entity 5905 | GrantCommon Stock | 10,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-054959 · doc4.xml · nonDerivative · entry 1 Holder Michael · CIK 0001515140 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,500 F1 · price: Reflects Restricted Stock Units, each representing a contingent right to be issued one share of Common Stock. These Restricted Stock Units vest in four equal annual installments upon the satisfaction of certain performance-based vesting criteria with respect to the particular portion of Restricted Stock Units. F2 · balance_after: Includes unvested Restricted Stock Units. Read SEC document |
| May 11, 2021 Filed May 12, 2021 01:52 UTC | AVITA Medical, Inc. RCEL · Entity 5905 | GrantStock Options (Right to Buy) · Derivative | 112,500 | $0.00 Strike: $19.91 | $0.00 |
DisclosureSEC source: 0001209191-21-031924 · doc4.xml · derivative · entry 1 Holder Michael · CIK 0001515140 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,500 Underlying: Common Stock · 112,500 shares Expires 2031-05-11 F1 · derivative.exercise_date: These Stock Options vest based on performance-based vesting criteria. Read SEC document |
| March 22, 2021 Filed Mar 25, 2021 22:48 UTC | AVITA Medical, Inc. RCEL · Entity 5905 | GrantStock Options (Right to Buy) · Derivative | 37,500 | $0.00 Strike: $22.25 | $0.00 |
DisclosureSEC source: 0001209191-21-023079 · doc4.xml · derivative · entry 1 Holder Michael · CIK 0001515140 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,500 Underlying: Common Stock · 37,500 shares Expires 2031-03-22 F1 · derivative.exercise_date: These Stock Options become exercisable in four equal annual installments beginning on March 22, 2022. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.